Skip to main content

Cookies

This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use. Please read our cookie policy for more information on the use of cookies on this website.

Top
  • COVID-19
    • COVID-19 Resources
  • Solutions
    • By Market
      • Academic Research
      • Agriculture
      • Biobanking
      • Government
      • Pharma and Biotech
      • Research Foundations
    • By Application
      • Clinical Trial Sample Management
      • Discovery, Compound Management and Biologics
      • Molecular Diagnostic Solutions
      • Regenerative Medicine and Cell Therapy
      • Sample Preparation and Lab Services
      • Sample Transport and Cold-Chain Logistics
      • Vaccine Development
    • Geography
      • Asia-Pacific
      • Europe
      • North America
  • Products
    • Azenta Life Sciences Virtual Booth
    • Automated Sample Storage Systems
      • Cold Storage (Ambient to -20°C)
      • Ultra Cold Storage (ULT -80°C)
      • Cryogenic Storage (-190°C)
    • Consumables & Instruments
      • Sample Tube Solutions
      • PCR & Microplate Solutions
      • Sample Cooling & Heating Labware
    • Informatics Platforms & LIMS/LIS
    • Integrations
    • Sterilization Services
    • Microplate Coding Services
  • Services
    • Genomics Services by GENEWIZ
    • Sample and Material Management Solutions
    • Sample and Material Storage
    • Clinical Trial Management
    • Drug Products Storage and Distribution
    • Sample Sourcing
    • Sample Prep and Lab Services
    • Lab Moving and Biological Transport
    • Business Continuity and Risk Mitigation
  • Support
    • Technical Support
    • Product Support Plans
    • Product Updates
    • Sample Tube Pack Request
    • Plate & Seal Sample Request
  • Resources
  • Blog
  • About Us
    • Events
    • About Azenta Life Sciences
    • Management Team
    • Board of Directors
    • Global Locations
    • Investor Relations
    • News
    • Careers
    • Quality
    • Certifications
  • Contact Us

Utility Navigation

  • Life Sciences Customer Login
  • GENEWIZ
  • BioInventory Login
  • Portals Login
  • Portals
  • Careers
Home

Utility Navigation

  • Life Sciences Customer Login
  • GENEWIZ
  • BioInventory Login
  • Portals Login
  • Portals
  • Careers

Main Navigation

  • COVID-19
    Vaccine Development
    Vaccine Development

    Accelerating global operations to manage and process samples critical to vaccine development.

    Azenta Life Sciences Virtual Booth
    Azenta Life Sciences Virtual Booth

    The exhibition experience to your desktop or mobile device

    • COVID-19 Resources
  • Solutions
    • By Market
      • Academic Research
      • Agriculture
      • Biobanking
      • Government
      • Pharma and Biotech
      • Research Foundations
    • By Application
      • Clinical Trial Sample Management
      • Discovery, Compound Management and Biologics
      • Molecular Diagnostic Solutions
      • Regenerative Medicine and Cell Therapy
      • Sample Preparation and Lab Services
      • Sample Transport and Cold-Chain Logistics
      • Vaccine Development
    • Geography
      • Asia-Pacific
      • Europe
      • North America
    Resources Center

    Learn about sample management best practices, gain advice from industry leaders, gain access to global regulatory and logistics guidelines and find simple support tools that can help you make better sample management decisions.

    Resources Center
  • Products
    Azenta Sample Pack and Catalog
    Sample Tube Pack Request

    Improve sample tracking, ensure sample integrity and drive process efficiency with Azenta Sample Storage Tubes. Explore the range, and select the best tube for your workflow.

    Low DNA Binding Microplates
    Low Binding Microplates

    Ultra low DNA binding microplates made from PP, fit for Next Generation Sequencing (NGS) and other sensitive applications with ultra-low DNA input. Off the shelf options. Custom solutions on request.

    • Azenta Life Sciences Virtual Booth
    • Automated Sample Storage Systems
      • Cold Storage (Ambient to -20°C)
      • Ultra Cold Storage (ULT -80°C)
      • Cryogenic Storage (-190°C)
    • Consumables & Instruments
      • Sample Tube Solutions
      • PCR & Microplate Solutions
      • Sample Cooling & Heating Labware
    • Informatics Platforms & LIMS/LIS
    • Integrations
    • Sterilization Services
    • Microplate Coding Services
  • Services
    Clinical Trial Management
    Clinical Trial Management

    Life science organizations must collect and manage large numbers of research samples to bring a new therapeutic or diagnostic to market. This is a complex process.

    Sample Preparation & Lab Analytical Services
    Genomics Services by GENEWIZ

    Comprehensive genomics services provide end to end solutions and best-in-class data quality from the trusted experts in genomics.

    • Genomics Services by GENEWIZ
    • Sample and Material Management Solutions
    • Sample and Material Storage
    • Clinical Trial Management
    • Drug Products Storage and Distribution
    • Sample Sourcing
    • Sample Prep and Lab Services
    • Lab Moving and Biological Transport
    • Business Continuity and Risk Mitigation
  • Support
    disaster recovery
    How Safe Are Your Samples?

    Plastic storage tubes are used in laboratories worldwide to store biological and chemical samples.

    Product Support Plans
    Product Support Plans

    Azenta  Life Sciences' world class service team is committed to ensuring you meet your business objectives by providing a flexible portfolio of service products designed to optimize up-time and productivity.

    • Technical Support
    • Product Support Plans
    • Product Updates
    • Sample Tube Pack Request
    • Plate & Seal Sample Request
  • Resources
  • Blog
  • About Us
    Putting a Sample Kit in an envelope
    Quality Assurance Certifications

    Azenta Life Sciences has established, documented, implemented and currently maintains a quality management system that fulfills the needs of customers.

    About Azenta Life Sciences
    About Azenta Life Sciences

    We are Azenta Life Sciences. We provide unrivaled sample exploration and management solutions to help our customers accelerate discovery, development and delivery.

    • Events
    • About Azenta Life Sciences
    • Management Team
    • Board of Directors
    • Global Locations
    • Investor Relations
    • News
    • Careers
    • Quality
    • Certifications
  • Contact Us

Blog

You are here

  • Home
  • Blog
  • Antibody Libraries for In Vitro Display: What to Consider

Antibody Libraries for In Vitro Display: What to Consider

February 2, 2022

Antibody Libraries for In Vitro Display: What to Consider

 

The strength of any display-based antibody discovery program hinges on its library. While all library types have the potential to generate antibodies with high affinity and specificity, they differ in how reliably leads generated from the screening process can be converted into viable candidates during development. The diversity (quantity of and variety between library sequences), functionality (capability to produce viable antibodies), and developability (commercially relevant considerations including recombinant expression level, solubility, stability, and immunogenicity) of sequences in the library govern the likelihood of generating successful candidates. Antibody libraries are typically derived from one or a combination of natural or synthetic sources including naïve B-cell repertoires, immunized donors, and combinatorial DNA synthesis. To help you decide which type of library is the most appropriate for your in vitro display experiment, we’ll look at the preparation, benefits, and challenges of each one.

 

Naïve Antibody Libraries

Advantages:

  • Functionally derived
  • Human sourcing
  • Faster production than immune (weeks)

Disadvantages:

  • Library bias from donor selection
  • Downstream optimization after screening

Compared to immunized repertoires, naïve libraries have a larger diversity as there is no or minimal antigen bias. The goal is to employ the full range of the human immunoglobulin repertoire for affinity maturation in vitro. These libraries are constructed from VH and VL sequences isolated from healthy human donors in a manner that is similar to immune libraries, minus the immunization step. They typically represent a pool of carefully selected donors to ensure a high diversity of sequences. Naïve libraries can be used to screen against a wide range of antigens; however, antibodies from these sources may be unpredictable for downstream developability. In any natural antibody library, toxicity to E. coli is not uncommon, making them incompatible with some popular screening technologies. Even candidates that exhibit favorable affinity and specificity through screening may also exhibit expression, solubility, or some other physiochemical or biological property that harms commercial viability. Consideration of the full scope of an antibody discovery and development program can avoid costly and time-intensive optimization downstream.

 

Immune Antibody Libraries

Advantages:

  • Functionally derived
  • Well-established and proven method

Disadvantages:

  • Slow to produce (months)
  • Non-human sourcing
  • Low compatibility with contemporary screening/development

Antibody repertoires derived from natural sources have the advantage of practical functionality that has been demonstrated in vivo. They can be isolated from immunized or non-immunized (naïve) sources with repertories of human or non-human origin. Using immune libraries for a display approach enables antibody selection both in vivo and in vitro. The adaptive immune system enriches B-cells that produce specific and functional antibodies against the antigen, and this population of immunoglobulin (Ig) sequences is further optimized through directed evolution via in vitro display. Library generation typically involves isolating B-cells from an immunized individual and cloning the variable regions of the heavy and light antibody chains into a vector (Figure 1). When originating from a non-human repertoire, antibody drugs carry an elevated risk of eliciting undesired immune responses in patients despite “humanization” of the antibody sequences post-selection. However, using transgenic animals—in which endogenous Ig genes have been replaced with human counterparts—significantly mitigates this risk. The genetic bias inherent in immune libraries effectively restricts the range of sequences that are screened in vitro, which has benefits and drawbacks. The reduced diversity improves the chances of isolating a functional candidate but limits the potential gains in affinity from in vitro selection.

Imune Library

Figure 1. Preparation of an immune antibody library. The target protein, or antigen, is introduced into an animal. Later, B-cells are subsequently isolated, and mRNA is purified. The V(D)J sequences are amplified (via RT-PCR) from the immunoglobulin heavy- and light-chain variable regions and cloned into a vector, such as a phagemid for phage display.

 

Synthetic Antibody Libraries

Advantages:

  • High degree of library control
  • Optimized meaningful diversity
  • Faster production than immune libraries (weeks)
  • Rational design based on project goals

Disadvantages:

  • Additional laboratory work required for synthesis

For the purposes of this discussion, we will focus exclusively on antibody libraries generated through chemical synthesis/modification rather than semi-synthetic repertoires. These libraries are designed in silico using data from a variety of sources including natural repertoire sequences and then constructed using current DNA synthesis technologies. Offering a high degree of control, this approach enables a “quality by design” approach that favors development. In a synthetic repertoire, molecular properties that are critical to commercial success can be a focal point of the library by using pre-optimized scaffolds from literature. Diversification takes place in targeted positions to maximize a range of binder selectivity while minimizing disruption to folding or other structural elements. This means that naturally variable domains such as the complementary determining regions (CDRs) are selectively mutated using a method such as combinatorial DNA synthesis, while framework regions are conserved to minimize developability biases.

 

Combinatorial Library Stop Codons Risk of Mutation ‘AT’ Rich Bias Assigned Amino Acids Screening Speed Screening Costs
Random (NNN) 3 High Possible No Slow $$$
Partially Random (NNK/NNS) 1 High Possible No Moderate $$
Trimer-Controlled 0 Low None Yes Fastest $

Table 1. Comparison of combinatorial synthetic DNA library techniques

 

The most common and simple method of CDR diversification uses randomized (NNN) or degenerate (NNK/NNS) mixtures of codons to create variants of a parent DNA sequence coding for an antibody (Table 1). Unfortunately, these methods can introduce stop codons or frameshift mutations into the library, creating a nonviable antibody and increasing the time and costs required for subsequent screening. Additionally, the randomized nature of oligonucleotide use in NNN/NNK/NNS libraries results in low precision for sequence diversification. Trinucleotide-directed mutagenesis (TRIM) or other trimer-controlled DNA synthesis techniques use pre-synthesized codon units to allow precise control of amino acid distribution and limitation of nonviable antibodies due to stop codon incorporation or disruptions to antibody folding from frameshift mutations. A smart synthetic method such as trimer-control enables precise construction of antibody libraries through deliberate protein design and codon optimization. Synthetic errors such as insertions or deletions can be minimized by using high-quality oligonucleotide building blocks and optimized DNA assembly protocols. A diversity analysis and quality control check of the library by Sanger or next-generation sequencing provides confidence in the final product.

 

Key Takeaways

  • Several factors should be considered when building an antibody library, including sequence diversity and the predictability of developing antibody leads (from in vitro screening) into viable candidates
  • Immune and naïve library generation techniques are proven to be effective for specific antigens, but possess inherent limitations for developability
  • Antibody libraries produced from synthetic DNA can be quickly and easily engineered to fit the biological and commercial goals of a development program

See how a trimer-controlled synthesis approach can boost the effectiveness of antibody libraries by downloading our case study.

 

Download Case Study

 

References

Shim, H. Synthetic approach to the generation of antibody diversity. BMB Rep. 2015, 48, 489-494.
Almagro, J. C.; Pedraza-Escalona, M.; Arrieta, H. I.; Pérez-Tapia, S. M. Phage Display Libraries for Antibody Therapeutic Discovery and Development. Antibodies 2019, 8, 44-65.
Lin, C.-W.; Lerner, R.A. Antibody Libraries as Tools to Discover Functional Antibodies and Receptor Pleiotropism. Int. J. Mol. Sci. 2021, 22, 4123-4134.
Chan S.K., Rahumatullah A., Lai J.Y., Lim T.S. (2017) Naïve Human Antibody Libraries for Infectious Diseases. In: Lim T. (eds) Recombinant Antibodies for Infectious Diseases. Advances in Experimental Medicine and Biology, vol 1053. Springer, Cham. https://doi.org/10.1007/978-3-319-72077-7_3

  • Genomics
  • Antibody Discovery
  • Gene Synthesis
Home
Facebook twitter youtube linkedin
Copyright © 2023 Azenta US, Inc.

Footer menu

  • Privacy Policy
  • Cookie Policy
  • Terms and Conditions
  • Terms of Use
  • Careers
  • Subscribe